Suven Life Sciences Ltd's Q4FY25 Quarter Results
- 14 May 2025
Result Summary
- Suven Life Sciences Ltd reported a 105.9% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Mar (Q4FY25). On a year-on-year (YoY) basis, it witnessed a decline of 18.8%.
- Its expenses for the quarter were down by 19.2% QoQ and 4.6% YoY.
- The net profit decreased 32.2% QoQ and decreased 4.0% YoY.
- The earnings per share (EPS) of Suven Life Sciences Ltd declined at 1.2 during Q4FY25.
Financial Statments for Q4FY25
| (₹ crores) | Q4FY25 | Q3FY25 | Q4FY24 | QoQ (%) | YoY (%) |
|---|---|---|---|---|---|
Total Income | 6.67 | 3.24 | 8.21 | 105.9% | -18.8% |
Total Expenses | 34.21 | 42.36 | 35.85 | -19.2% | -4.6% |
Profit Before Tax | -27.54 | -39.12 | -27.64 | -29.6% | -0.4% |
Tax | -1.00 | 0.00 | 0.00 | - | - |
Profit After Tax | -26.54 | -39.12 | -27.64 | -32.2% | -4.0% |
Earnings Per Share | -1.20 | -1.80 | -1.20 | -33.3% | 0.0% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Suven Life Sciences Ltd is an Indian biopharmaceutical company primarily involved in the discovery of novel therapeutic molecules with a focus on central nervous system (CNS) disorders. The company is engaged in contract research and manufacturing services (CRAMS) and has been involved in the development of drugs for various neurodegenerative disorders such as Alzheimer's disease, schizophrenia, and depression. While recent major developments are not specified, Suven Life Sciences has historically focused on advancing its pipeline of CNS-targeted drugs through various stages of clinical development. The company operates in the highly competitive and research-intensive pharmaceutical industry, which is characterized by significant investments in research and development activities.
Revenue
In the fourth quarter of the fiscal year 2025 (Q4FY25), Suven Life Sciences Ltd reported a total income of ₹6.67 crores. This represents a substantial quarter-over-quarter (QoQ) increase of 105.9% compared to the third quarter of the fiscal year 2025 (Q3FY25), where the total income was ₹3.24 crores. However, when compared year-over-year (YoY) to the fourth quarter of the fiscal year 2024 (Q4FY24), there was a decline of 18.8% from an income of ₹8.21 crores. These fluctuations in revenue may reflect changes in the company's operational activities, market conditions, or external factors impacting the pharmaceutical industry.
Profitability
Profitability for Suven Life Sciences Ltd in Q4FY25 saw a loss before tax of ₹27.54 crores, which is an improvement from the loss of ₹39.12 crores reported in Q3FY25, reflecting a QoQ improvement of 29.6%. On a YoY basis, the loss before tax in Q4FY24 was ₹27.64 crores, showing a marginal decrease of 0.4%. The company also reported a profit after tax of -₹26.54 crores in Q4FY25, compared to -₹39.12 crores in Q3FY25, representing a 32.2% QoQ improvement. Year-over-year, the profit after tax slightly improved by 4.0% from Q4FY24's -₹27.64 crores. Earnings per share (EPS) remained constant year-over-year at -₹1.20, though it showed a 33.3% QoQ improvement from -₹1.80 in Q3FY25.
Operating Metrics
Total expenses for Suven Life Sciences Ltd in Q4FY25 were reported at ₹34.21 crores, which is a decrease of 19.2% from the ₹42.36 crores reported in Q3FY25. This reduction in expenses may suggest cost control measures or changes in operational activities. Year-over-year, total expenses decreased by 4.6% from ₹35.85 crores in Q4FY24. The tax burden for the company in Q4FY25 was reported at -₹1.00 crore, with no tax reported in Q3FY25 and Q4FY24. The company's operational performance, as indicated by these financial metrics, reflects various factors that could include efficiency improvements, cost management strategies, or other operational adjustments.
